Medtech company Ultromics sees $33m in Series B funding round
International law firm Fieldfisher has advised Oxford-based MedTech company Ultromics on its $33m Series B funding round led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.
Ultromics was founded in 2017 by Dr Ross Upton and Professor Paul Leeson, as a spin-out from the University of Oxford and built-in partnership with the U.K.’s National Health Service (NHS).
Ultromics’ EchoGo Core and EchoGo Pro platforms quickly deliver highly accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis. The company also provides autonomous echocardiography analysis through innovative AI solutions.
Ultromics plans to use the Series B funding to accelerate validating and scaling their technology with the support of their investors.
Dr. Janita Good, co-head of Life Sciences at Fieldfisher commented: “We are delighted to have worked with Ultromics on this crucial fundraising. Ultromics’ ground-breaking technology has the power to revolutionise the way healthcare providers diagnose and then treat cardiovascular disease.
“This fundraising is another example of the appetite for the much-needed innovation that comes from the UK life sciences sector.
“Fieldfisher’s life sciences sector group has a strong reputation for working with the world’s most innovative life sciences companies bringing about real change in healthcare.
“We wish Ultromics every success in the future and look forward to seeing how they continue to grow internationally.”